stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Revenue growth
GSK PLC Sponsored ADR's revenue growth over the twelve months to 30 September 2026 was 6.90%, down 0.5 percentage points from fiscal 2025 (7.44%). Over the past ten years it has ranged from −22.7% (fiscal 2022) to 7.44% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Drug Manufacturers General industry median of 6.72% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 7.44% | 1.16 |
| FY2024 | 6.28% | 2.27 |
| FY2023 | 4.01% | 26.69 |
| FY2022 | −22.7% | (29.82) |
| FY2021 | 7.14% | 5.56 |
| FY2020 | 1.58% | (3.19) |
| FY2019 | 4.77% | (0.98) |
| FY2018 | 5.75% | 2.82 |
| FY2017 | 2.93% | (0.40) |
| FY2016 | 3.33% | 6.86 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 3.75% | (2.06) |
| Jun 2026 | 5.81% | (2.79) |
| Mar 2026 | 8.60% | (1.39) |
| Dec 2025 | 9.99% | (0.57) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SNY Sanofi compare | 26.3% |
| NVO Novo Nordisk A/S compare | 13.2% |
| AMGN Amgen Inc. compare | 8.15% |
| AZN AstraZeneca PLC compare | 7.32% |
| GSK GSK PLC Sponsored ADR | 6.90% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| BIIB Biogen Inc. compare | 2.30% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement